株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

C型肝炎 : パイプライン分析

Hepatitis C - Pipeline Review, H1 2017

発行 Global Markets Direct 商品コード 232778
出版日 ページ情報 英文 443 Pages
即納可能
価格
本日の銀行送金レート: 1USD=112.79円で換算しております。
Back to Top
C型肝炎 : パイプライン分析 Hepatitis C - Pipeline Review, H1 2017
出版日: 2017年04月28日 ページ情報: 英文 443 Pages
概要

C型肝炎は、肝臓の感染性のウイルス感染で、感染した血との接触で拡大します。症状は穏やかな場合もありますが、長期に渡って長引き、様々な合併症を引き起こすこともあります。 特徴的な症候は腹痛、疲労、熱、黄疸、食欲不振、吐き気、嘔吐などがあります。素因としては透析、臓器移植、輸血などが挙げられます。また、母子感染のリスクもあります。 C型肝炎は、進行した段階で薬物療法または移植で管理します。

当レポートでは、C型肝炎の治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

イントロダクション

  • C型肝炎 概要

治療薬の開発

企業で開発中の治療薬

大学/機関で研究中の治療薬

パイプライン製品の概況

企業で開発中の製品

大学/機関で研究中の製品

治療薬開発に従事している企業

治療薬の評価

薬剤プロファイル

最近のパイプライン動向

休止中のプロジェクト

開発が中止された製品

製品開発のマイルストーン

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC9199IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hepatitis C - Pipeline Review, H1 2017, provides an overview of the Hepatitis C (Infectious Disease) pipeline landscape.

Hepatitis C is a contagious viral infection affecting the liver. It may spread on contact with infected blood. It may be a mild condition or may extend over a longer span of time leading to various complications. The characteristic symptoms include abdominal pain, fatigue, fever, jaundice, loss of appetite, nausea and vomiting The predisposing factors of hepatitis C include dialysis, organ transplant and blood transfusion. Offspring of an infected mother also has high chances of contracting the disease. Hepatitis C can be controlled with the help of medications or a transplant at an advanced stage.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hepatitis C - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Hepatitis C (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hepatitis C (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Hepatitis C and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 13, 23, 15, 1, 52, 45 and 4 respectively. Similarly, the Universities portfolio in Phase II, IND/CTA Filed, Preclinical and Discovery stages comprises 3, 1, 9 and 23 molecules, respectively.

Hepatitis C (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hepatitis C (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Hepatitis C (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hepatitis C (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hepatitis C (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hepatitis C (Infectious Disease)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hepatitis C (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hepatitis C (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Hepatitis C - Overview
  • Hepatitis C - Therapeutics Development
  • Hepatitis C - Therapeutics Assessment
  • Hepatitis C - Companies Involved in Therapeutics Development
  • Hepatitis C - Drug Profiles
  • Hepatitis C - Dormant Projects
  • Hepatitis C - Discontinued Products
  • Hepatitis C - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Hepatitis C, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..4), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..5), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..6), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..7), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..8), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Hepatitis C - Pipeline by 3-V Biosciences Inc, H1 2017
  • Hepatitis C - Pipeline by AbbVie Inc, H1 2017
  • Hepatitis C - Pipeline by AIMM Therapeutics BV, H1 2017
  • Hepatitis C - Pipeline by Akshaya Bio Inc, H1 2017
  • Hepatitis C - Pipeline by Amarillo Biosciences Inc, H1 2017
  • Hepatitis C - Pipeline by Amarna Therapeutics BV, H1 2017
  • Hepatitis C - Pipeline by ARA Healthcare Pvt Ltd, H1 2017
  • Hepatitis C - Pipeline by Aviragen Therapeutics Inc, H1 2017
  • Hepatitis C - Pipeline by Beijing Kawin Technology Share-Holding Co Ltd, H1 2017
  • Hepatitis C - Pipeline by Beta Pharma Inc, H1 2017
  • Hepatitis C - Pipeline by Biocad, H1 2017
  • Hepatitis C - Pipeline by Biotest Pharmaceuticals Corp, H1 2017
  • Hepatitis C - Pipeline by Biotron Ltd, H1 2017
  • Hepatitis C - Pipeline by Boehringer Ingelheim GmbH, H1 2017
  • Hepatitis C - Pipeline by Bolder Biotechnology Inc, H1 2017
  • Hepatitis C - Pipeline by Bristol-Myers Squibb Company, H1 2017
  • Hepatitis C - Pipeline by Cocrystal Pharma Inc, H1 2017
  • Hepatitis C - Pipeline by Conatus Pharmaceuticals Inc, H1 2017
  • Hepatitis C - Pipeline by ContraVir Pharmaceuticals Inc, H1 2017
  • Hepatitis C - Pipeline by DEKK-TEC Inc, H1 2017
  • Hepatitis C - Pipeline by Delpor Inc, H1 2017
  • Hepatitis C - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
  • Hepatitis C - Pipeline by Formune SL, H1 2017
  • Hepatitis C - Pipeline by Genecode AS, H1 2017
  • Hepatitis C - Pipeline by GeneCure LLC, H1 2017
  • Hepatitis C - Pipeline by Gilead Sciences Inc, H1 2017
  • Hepatitis C - Pipeline by GinkgoPharma Co Ltd, H1 2017
  • Hepatitis C - Pipeline by GlaxoSmithKline Plc, H1 2017
  • Hepatitis C - Pipeline by HanAll Biopharma Co Ltd, H1 2017
  • Hepatitis C - Pipeline by ImmunoBiology Ltd, H1 2017
  • Hepatitis C - Pipeline by ImmunoClin Corp, H1 2017
  • Hepatitis C - Pipeline by Immunotope Inc, H1 2017
  • Hepatitis C - Pipeline by Inovio Pharmaceuticals Inc, H1 2017
  • Hepatitis C - Pipeline by Integrated BioTherapeutics Inc, H1 2017
  • Hepatitis C - Pipeline by JN-International Medical Corp, H1 2017
  • Hepatitis C - Pipeline by Johnson & Johnson, H1 2017
  • Hepatitis C - Pipeline by Karyopharm Therapeutics Inc, H1 2017
  • Hepatitis C - Pipeline by Kineta Inc, H1 2017
  • Hepatitis C - Pipeline by Ligand Pharmaceuticals Inc, H1 2017
  • Hepatitis C - Pipeline by Medivir AB, H1 2017
  • Hepatitis C - Pipeline by Merck & Co Inc, H1 2017
  • Hepatitis C - Pipeline by Microbio Co Ltd, H1 2017
  • Hepatitis C - Pipeline by Microbiotix Inc, H1 2017
  • Hepatitis C - Pipeline by MultiCell Technologies Inc, H1 2017
  • Hepatitis C - Pipeline by NeuroVive Pharmaceutical AB, H1 2017
  • Hepatitis C - Pipeline by Novalex Therapeutics Inc, H1 2017
  • Hepatitis C - Pipeline by Novartis AG, H1 2017
  • Hepatitis C - Pipeline by NovaTarg Therapeutics Inc, H1 2017
  • Hepatitis C - Pipeline by Ono Pharmaceutical Co Ltd, H1 2017
  • Hepatitis C - Pipeline by Pfenex Inc, H1 2017
  • Hepatitis C - Pipeline by Pfizer Inc, H1 2017
  • Hepatitis C - Pipeline by PharmaEssentia Corp, H1 2017
  • Hepatitis C - Pipeline by Presidio Pharmaceuticals Inc, H1 2017
  • Hepatitis C - Pipeline by Profectus BioSciences Inc, H1 2017
  • Hepatitis C - Pipeline by Replicor Inc, H1 2017
  • Hepatitis C - Pipeline by Rodos BioTarget GmbH, H1 2017
  • Hepatitis C - Pipeline by Solon Eiendom ASA, H1 2017
  • Hepatitis C - Pipeline by SomaGenics Inc, H1 2017
  • Hepatitis C - Pipeline by Sorrento Therapeutics Inc, H1 2017
  • Hepatitis C - Pipeline by Sudershan Biotech Ltd, H1 2017
  • Hepatitis C - Pipeline by TaiGen Biotechnology Co Ltd, H1 2017
  • Hepatitis C - Pipeline by TaiwanJ Pharmaceuticals Co Ltd, H1 2017
  • Hepatitis C - Pipeline by Therapure Biopharma Inc, H1 2017
  • Hepatitis C - Pipeline by Theravectys SA, H1 2017
  • Hepatitis C - Pipeline by THEVAX Genetics Vaccine USA Inc, H1 2017
  • Hepatitis C - Pipeline by Vakzine Projekt Management GmbH, H1 2017
  • Hepatitis C - Pipeline by Vertex Pharmaceuticals Inc, H1 2017
  • Hepatitis C - Pipeline by WhanIn Pharmaceutical Co Ltd, H1 2017
  • Hepatitis C - Pipeline by Zylacta Corp, H1 2017
  • Hepatitis C - Dormant Projects, H1 2017
  • Hepatitis C - Dormant Projects, H1 2017 (Contd..1), H1 2017
  • Hepatitis C - Dormant Projects, H1 2017 (Contd..2), H1 2017
  • Hepatitis C - Dormant Projects, H1 2017 (Contd..3), H1 2017
  • Hepatitis C - Dormant Projects, H1 2017 (Contd..4), H1 2017
  • Hepatitis C - Dormant Projects, H1 2017 (Contd..5), H1 2017
  • Hepatitis C - Dormant Projects, H1 2017 (Contd..6), H1 2017
  • Hepatitis C - Dormant Projects, H1 2017 (Contd..7), H1 2017
  • Hepatitis C - Dormant Projects, H1 2017 (Contd..8), H1 2017
  • Hepatitis C - Dormant Projects, H1 2017 (Contd..9), H1 2017
  • Hepatitis C - Dormant Projects, H1 2017 (Contd..10), H1 2017
  • Hepatitis C - Dormant Projects, H1 2017 (Contd..11), H1 2017
  • Hepatitis C - Dormant Projects, H1 2017 (Contd..12), H1 2017
  • Hepatitis C - Dormant Projects, H1 2017 (Contd..13), H1 2017
  • Hepatitis C - Dormant Projects, H1 2017 (Contd..14), H1 2017
  • Hepatitis C - Dormant Projects, H1 2017 (Contd..15), H1 2017
  • Hepatitis C - Dormant Projects, H1 2017 (Contd..16), H1 2017
  • Hepatitis C - Discontinued Products, H1 2017
  • Hepatitis C - Discontinued Products, H1 2017 (Contd..1), H1 2017
  • Hepatitis C - Discontinued Products, H1 2017 (Contd..2), H1 2017
  • Hepatitis C - Discontinued Products, H1 2017 (Contd..3), H1 2017
  • Hepatitis C - Discontinued Products, H1 2017 (Contd..4), H1 2017

List of Figures

  • Number of Products under Development for Hepatitis C, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Top 10 Molecule Types, H1 2017
  • Number of Products by Stage and Top 10 Molecule Types, H1 2017
Back to Top